MB1a(4A8)

(0) No Reviews yet
$40.00
SKU: MB1a(4A8)
View product citations for antibody MB1a(4A8) on CiteAb

In Stock

Available: 150

DSHB Data Sheet

Catalog Fields

Antigen: Muscleblind-like splicing regulator 1
Hybridoma Cells Available: Yes
Antigen Species: Human
Depositor: Morris, G.E.
Isotype: MIgG1
Antigen Sequence:
Host Species: mouse
Depositors Institution: Centre for Inherited Neuromuscular Disease, RJAH Orthopaedic Hospital
Positive Tested Species Reactivity: Human, Mouse
Depositors Notes: MB1a(4A8) does not cross-react with MBNL2 or MBNL3 isoforms.
Antigen Molecular Weight: 42 kDa
Human Protein Atlas:  
Predicted Species Reactivity:  
Gene: MBNL1
Immunogen: His-tagged recombinant MBNL1 expressed in E. coli
Alternate Gene Names: EXP, EXP35, EXP40, EXP42
Alternate Antibody Name:
Clonality: Monoclonal
Alternate Antigen Name:
Epitope Mapped: Yes
Myeloma Strain: Sp2/0
Epitope Location or Sequence: a.a. VSPSL/ linker between two zinc fingers in MBNL1 exon 3
Uniprot ID: Q9NR56 
Immunogen Sequence: Full length protein
Entrez Gene ID: 4154 
Antibody Registry ID: AB_2618248 
Additional Information: RRID:AB_2618248
Recommended Applications: ELISA, Immunofluorescence, Immunohistochemistry, Western Blot
These hybridomas were created by your colleagues. Please acknowledge the hybridoma contributor and the Developmental Studies Hybridoma Bank (DSHB) in the Materials and Methods of your publications. Please email the citation to us.
For your Materials & Methods section:
MB1a(4A8) was deposited to the DSHB by Morris, G.E. (DSHB Hybridoma Product MB1a(4A8))
Storage and Handling Recommendations
Although many cell products are maintained at 4°C for years without loss of activity, shelf-life at 4°C is highly variable. For immediate use, short term storage at 4°C up to two weeks is recommended. For long term storage, divide the solution into volumes of no less than 20 ul for freezing at -20°C or -80°C. The small volume aliquot should provide sufficient reagent for short term use. Freeze-thaw cycles should be avoided. For concentrate or bioreactor products, an equal volume of glycerol, a cryoprotectant, may be added prior to freezing.
Usage Recommendations
Although the optimal Ig concentration for an application varies for each product and must be optimized for each laboratory, a good starting concentration for immunohistochemistry (IHC), immunofluorescence (IF), and immunocytochemistry (ICC) is 2-5 ug/ml. For western blots, the recommended concentration range is 0.2-0.5 ug/ml.
All cell products contain the antimicrobial ProClin. Click here for additional information.

13 References

  • Initial Publication
  • IF References
  • WB References
  • IHC References
  • ELISA References
  • Epitope Map References
  • All References
  • Initial Publication

    Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles.
    Morris GE
    Genes to cells : devoted to molecular & cellular mechanisms 12.9 (2007 Sep): 1035-48.

    IF References

    The nuclear concentration required for antisense oligonucleotide activity in myotonic dystrophy cells.
    Brock R
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 33.10 (2019 Oct): 11314-11325.

    Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles.
    Morris GE
    Genes to cells : devoted to molecular & cellular mechanisms 12.9 (2007 Sep): 1035-48.

    Actinomycin D Specifically Reduces Expanded CUG Repeat RNA in Myotonic Dystrophy Models.
    Berglund JA
    Cell reports 13.11 (2015 Dec 22): 2386-2394.

    Biological Efficacy and Toxicity of Diamidines in Myotonic Dystrophy Type 1 Models.
    Berglund JA
    Journal of medicinal chemistry 58.15 (2015 Aug 13): 5770-80.

    Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice.
    Puymirat J
    Molecular therapy. Nucleic acids 7. (2017 Jun 16): 465-474.

    The nuclear concentration required for antisense oligonucleotide activity in myotonic dystrophy cells.
    Brock R
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 33.10 (2019 Oct): 11314-11325.

    Intrinsic Myogenic Potential of Skeletal Muscle-Derived Pericytes from Patients with Myotonic Dystrophy Type 1.
    van Bokhoven H
    Molecular therapy. Methods & clinical development 15. (2019 Dec 13): 120-132.

    CRISPR/Cas9-Induced (CTG⋅CAG)<sub>n</sub> Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing.
    Wieringa B
    Molecular therapy : the journal of the American Society of Gene Therapy 25.1 (2017 Jan 4): 24-43.

    Bioengineered<i>in vitro</i>3D model of myotonic dystrophy type 1 human skeletal muscle.
    Ramon J
    Biofabrication . (2021 Apr 9): .

    WB References
    IHC References

    Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles.
    Morris GE
    Genes to cells : devoted to molecular & cellular mechanisms 12.9 (2007 Sep): 1035-48.

    Muscleblind-like proteins: similarities and differences in normal and myotonic dystrophy muscle.
    Morris GE
    The American journal of pathology 174.1 (2009 Jan): 216-27.

    ELISA References

    Muscleblind-like proteins: similarities and differences in normal and myotonic dystrophy muscle.
    Morris GE
    The American journal of pathology 174.1 (2009 Jan): 216-27.

    Epitope Map References

    Muscleblind-like proteins: similarities and differences in normal and myotonic dystrophy muscle.
    Morris GE
    The American journal of pathology 174.1 (2009 Jan): 216-27.

    All References

    Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles.
    Morris GE
    Genes to cells : devoted to molecular & cellular mechanisms 12.9 (2007 Sep): 1035-48.

    Muscleblind-like proteins: similarities and differences in normal and myotonic dystrophy muscle.
    Morris GE
    The American journal of pathology 174.1 (2009 Jan): 216-27.

    The nuclear concentration required for antisense oligonucleotide activity in myotonic dystrophy cells.
    Brock R
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 33.10 (2019 Oct): 11314-11325.

    Actinomycin D Specifically Reduces Expanded CUG Repeat RNA in Myotonic Dystrophy Models.
    Berglund JA
    Cell reports 13.11 (2015 Dec 22): 2386-2394.

    Biological Efficacy and Toxicity of Diamidines in Myotonic Dystrophy Type 1 Models.
    Berglund JA
    Journal of medicinal chemistry 58.15 (2015 Aug 13): 5770-80.

    Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice.
    Puymirat J
    Molecular therapy. Nucleic acids 7. (2017 Jun 16): 465-474.

    Intrinsic Myogenic Potential of Skeletal Muscle-Derived Pericytes from Patients with Myotonic Dystrophy Type 1.
    van Bokhoven H
    Molecular therapy. Methods & clinical development 15. (2019 Dec 13): 120-132.

    CRISPR/Cas9-Induced (CTG⋅CAG)<sub>n</sub> Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing.
    Wieringa B
    Molecular therapy : the journal of the American Society of Gene Therapy 25.1 (2017 Jan 4): 24-43.

    Bioengineered<i>in vitro</i>3D model of myotonic dystrophy type 1 human skeletal muscle.
    Ramon J
    Biofabrication . (2021 Apr 9): .

    Muscleblind-like 1 (Mbnl1) regulates pre-mRNA alternative splicing during terminal erythropoiesis.
    Lodish HF
    Blood 124.4 (2014 Jul 24): 598-610.

    Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy.
    Berglund JA
    PLoS genetics 12.9 (2016 Sep): e1006316.

    Progressive Cl- channel defects reveal disrupted skeletal muscle maturation in R6/2 Huntington's mice.
    Voss AA
    The Journal of general physiology 149.1 (2017 Jan): 55-74.

    New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats.
    Marie J
    Nucleic acids research 40.7 (2012 Apr): 3159-71.

    Ratings & Reviews

    No reviews available

    Be the first to Write a Review